Joanna Szydzik Exploring novel therapeutic strategies in neuroblastoma

Figure 2.1, Overall survival among patients with locally advanced Non-Small Cell Lung Carcinoma depending on during which time interval patients received their treatment

DSA and NDSA) detected using newer sensitive assays in kidney transplant recipients on graft function and survival, and 2) to examine the outcomes of recipients with positive FCXM

2002-2017 were reviewed. In total, 234 patients had received a diagnostic code for CS. Of these, 80 patients had endogenous CS and were included in the study. Validation of

The likelihood of inpatient care during last three months of life, including the expected number of hospital admissions, was significantly higher among residents

Background: Obstetric brachial plexus palsy (OBPP) at birth is one important cause of neurological disability in children and adults; the incidence has increased substantially in

Thus, using the naïve response as reference AMPA signaling in the neonatal CA3-CA1 synapse was quickly diminished by the low-frequency stimulation, while the NMDA responses

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.. Pathobiology of ALK+ anaplastic

Szydzik, J, Lind, DE, Umapathy, G, Hallberg, B and Palmer, RH, Modulation of SUN2 phosphorylation downstream of ALK pathway identifies a role for ATR in neuroblastoma